Skip to main content
. 2015 Apr 8;5:9465. doi: 10.1038/srep09465

Figure 2. TGX221 selectively inhibited RCC cells with both VHL and SETD2 mutations.

Figure 2

Reproduction of Genomics of Drug Sensitivity in Cancer (GDSC) database by excluding cancer of other types showed that RCC cells with (A) SETD2 or (B) VHL mutations was not significantly inhibited by TGX221. Five RCC cell lines were selected for VHL/SEDT2 status validation. (C) A498 and A704 cells harboured mutations in both VHL and SETD2. (D) Proliferation assay using TGX221 at 5 μM showing RCC cells with both VHL and SETD2 mutations were selectively inhibited by TGX221.